Therapeutic plasma exchange has emerged from a niche autoimmune treatment into a flagship longevity procedure offered by elite clinics. Here's what the heterochronic parabiosis research actually showed, what TPE does in humans, and whether the $5,000–15,000 cost is justified.
In 2005, Conboy et al. published a paper in *Nature* showing that surgically connecting the circulatory systems of young and old mice (heterochronic parabiosis) rejuvenated the older mouse's tissues. Specifically, old muscle stem cells regained the capacity to repair damaged muscle, old liver tissue reactivated juvenile gene expression patterns, and old neural progenitor cells resumed dividing. The implication was striking: there are circulating factors in young blood that maintain youthful tissue function, and removing those factors (or replacing them) might be a tractable longevity intervention.
Two decades later, therapeutic plasma exchange (TPE) — replacing a substantial fraction of a patient's plasma with donor plasma or albumin solution — has become the most popular elite longevity clinic procedure based on this hypothesis. This article reviews what the research actually shows in humans, what TPE does mechanistically, the costs, and how to evaluate whether the procedure is worth the very substantial price.
The Conboy mouse experiments were striking but specifically demonstrated that young blood factors rejuvenated old tissue. Subsequent work by the same group revealed an asymmetric effect: removing aging-promoting factors from old blood was nearly as beneficial as adding youth factors. This led to the dilution hypothesis — that the age-related increase in pro-inflammatory and senescence-promoting circulating factors may be the primary driver of systemic aging, and that diluting these factors (without replacement with young blood) might capture much of the benefit.
A landmark 2020 paper by the Conboy group showed that simple plasma exchange with saline + albumin in old mice produced rejuvenation comparable to true heterochronic parabiosis. This is the scientific foundation for human TPE protocols.
TPE is a clinical procedure used for decades in autoimmune disease (myasthenia gravis, Guillain-Barré, ANCA vasculitis, TTP). Mechanically: a needle in one arm draws blood through an apheresis machine, which separates plasma from cellular components. The plasma is discarded; the cellular components are returned to the patient mixed with replacement fluid (typically 5% albumin solution, sometimes fresh frozen plasma).
A typical session removes ~70% of circulating plasma proteins and replaces them with new albumin. This includes inflammatory cytokines, autoantibodies, immune complexes, and various senescence-associated factors. Each session takes 2–3 hours.
The most-cited human longevity TPE work is from Dobri Kiprov's clinic in California and parallel work in academic centers. Findings to date:
The evidence base is mostly observational from clinics performing the procedure. Randomized controlled trials of TPE for healthspan endpoints are ongoing as of 2026 but have not yet reported.
There is no universally agreed protocol. Common patterns:
Conservative: 2–4 sessions over 4 weeks, then quarterly maintenance
Standard: monthly TPE sessions for 6 months, then quarterly maintenance
Intensive: weekly TPE for 4 weeks, then monthly maintenance for 6 months
Cost per session ranges from $1,500 (academic medical center) to $5,000+ (elite longevity clinic). Total annual costs: $5,000–25,000 depending on protocol intensity.
Several claims about TPE outpace the evidence:
For most longevity-focused users, the math doesn't favor TPE. The same $10,000–25,000 annual budget could fund:
The TPE math may favor users who:
Markers of a credible operation:
1. Physician-led with apheresis-trained staff (TPE is a real medical procedure with real risks)
2. Replacement fluid is hospital-grade albumin, not "stem cell-rich" or other unproven additions
3. Pre-procedure laboratory screening (coagulation, complete blood count, electrolytes, calcium)
4. Side effect monitoring during and after procedure
5. Realistic discussion of what the data shows and doesn't show
TPE has real risks even in healthy users:
The procedure is generally safe in healthy adults but is not without risk.
Several elite clinics now combine TPE with stem cell infusion — the theory being that removing aging-promoting factors first creates a more receptive environment for stem cell engraftment. Evidence for additive benefit is anecdotal.
For the broader young blood / blood replacement landscape, see our piece on Young Blood Factors and Aging and Stem Cell Therapy for Anti-Aging in 2026.
Will TPE make me look younger?
Subjective reports include skin appearance changes, but objective skin aging measures haven't been studied rigorously. Don't expect a cosmetic procedure level of visible change.
How long do effects last?
Inflammatory marker reductions last 4–8 weeks. Epigenetic changes (where present) last longer. Most patients require quarterly maintenance.
Is TPE FDA-approved for longevity?
No. TPE is FDA-approved for specific autoimmune indications. Off-label use for longevity is legal but not FDA-evaluated.
Can I do TPE at home?
No. TPE requires medical-grade apheresis equipment and trained staff. Cannot be done outside a clinical setting.